Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Antiarrhythmic medications Clear all

Conditions: Atrial Fibrillation
Interventions: Medtronic Cardiac Ablation System, Class I or III Antiarrhythmic Medications; Procedure · Drug
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 23
States / cities: Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 18 more

Conditions: Atrial Fibrillation, Stroke
Interventions: Catheter Ablation, Market-approved AVNB, OAC and AAD; Device · Drug
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Overland Park, Kansas • Independence, Missouri • Kansas City, Missouri

Conditions: Atrial Fibrillation
Interventions: Cardiac CryoCor Cryoablation System, Medical management; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 24
States / cities: Sacramento, California • San Diego, California • San Francisco, California + 21 more

Conditions: Atrial Fibrillation, Arrhythmia
Interventions: Rate Control, Ablation Therapy, Rhythm control; Drug · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 10
States / cities: Birminham, Alabama • Los Angeles, California • Maywood, Illinois + 7 more

Conditions: Atrial Fibrillation
Interventions: Endoscopic Ablation System, Standard Anti-arrhythmic Drug (AAD) Therapy; Device · Drug
Lead sponsor: CardioFocus; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 18
States / cities: Scottsdale, Arizona • Sacramento, California • San Francisco, California + 15 more

Conditions: Atrial Fibrillation
Interventions: Pulmonary Vein Isolation performed by Catheter Ablation, Conventional Antiarrhythmic Drug Therapy; Procedure · Drug
Lead sponsor: Population Health Research Institute; Other
Eligibility: 19 Years to 75 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Austin, Texas

Conditions: Atrial Fibrillation
Interventions: Flecainide, Sotalol; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 100 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 4
States / cities: Chicago, Illinois • Oak Lawn, Illinois

Conditions: Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Diseases
Interventions: Beta blocker; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 65 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrial Fibrillation, Arrhythmia
Interventions: Left atrial ablation, Rate or Rhythm Control Therapy; Device · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 2,204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 76
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 66 more

Conditions: Tachycardia, Ventricular, Catheter Ablation
Interventions: Antiarrhythmic drug; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Persistent Atrial Fibrillation
Interventions: FARAPULSE™ Pulsed Field Ablation System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 33
States / cities: Mobile, Alabama • Jonesboro, Arkansas • Los Angeles, California + 29 more

Conditions: Atrial Fibrillation, Atrial Fibrillation New Onset
Interventions: Cryoablation, Antiarrhythmic drug; Device · Drug
Lead sponsor: Medtronic Cardiac Ablation Solutions; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 24
States / cities: Birmingham, Alabama • Anchorage, Alaska • Newport Beach, California + 21 more

Conditions: Congestive Heart Failure, Left Ventricular Failure, Atrial Fibrillation
Interventions: Catheter Ablation, FDA approved anti arrhythmic drug; Device · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Hartford, Connecticut • Akron, Ohio • Cleveland, Ohio + 3 more

Conditions: Atrial Fibrillation
Interventions: Cardiologs; Device
Lead sponsor: Cardiologs Technologies; Industry
Eligibility: 22 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atrial Fibrillation, Medication Adherence
Interventions: Education and telephone follow-up; Other
Lead sponsor: Creighton University; Other
Eligibility: 19 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 3
States / cities: Lincoln, Nebraska • Omaha, Nebraska

Conditions: Ventricular Tachycardia
Interventions: Ventricular Tachycardia Ablation, ICD Implant, Antiarrhythmic drug, EKG, Cardioversion, Echocardiogram; Procedure · Device · Drug + 1 more
Lead sponsor: CorVita Science Foundation; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atrial Fibrillation, Atrial Fibrillation Recurrent
Interventions: dronedarone 400 mg Oral Tablet, Placebo; Drug
Lead sponsor: Tulane University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Colorado Springs, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 1 more

Conditions: Cardiac Arrhythmia
Interventions: Osteopathic Manipulative Treatment, Light Touch Therapy; Procedure
Lead sponsor: New York Institute of Technology; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Glen Head, New York

Conditions: Atrial Fibrillation
Interventions: propafenone, flecainide, dofetilide, sotolol, Pulmonary vein ablation, Amiodarone; Drug · Device
Lead sponsor: ProRhythm, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 20
States / cities: Fullerton, California • Los Angeles, California • Atlanta, Georgia + 16 more

Conditions: Atrial Fibrillation
Interventions: No AAD post Ablation.; Other
Lead sponsor: Prisma Health-Midlands; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Ventricular Tachycardia
Interventions: Ventricular Tachycardia Ablation, Standard Medical Therapy, Non-Invasive Programmed Stimulation (NIPS); Procedure · Other
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Heart Diseases, Arrhythmia, Atrial Fibrillation
Interventions: NAVISTAR® THERMOCOOL® Catheter, Antiarrhythmic drug; Device · Drug
Lead sponsor: Biosense Webster, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 13
States / cities: Greenbrae, California • Orlando, Florida • Maywood, Illinois + 9 more

Conditions: Atrial Fibrillation
Interventions: propafenone; flecainide; sotalol; dofetilide, Radiofrequency catheter ablation; Drug · Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Atrial Fibrillation
Interventions: Anti Arrhythmics, Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation; Drug · Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Tucson, Arizona • The Bronx, New York • Cleveland, Ohio + 1 more

Search by objective public record fields.

Tailored Treatment of Permanent Atrial Fibrillation

Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control

Safety and Efficacy of CryoCor™ Cryoablation for PAF

Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial

Pivotal Clinical Study of Endoscopic Ablation for Atrial Fibrillation (AF) in Patients That Have Failed Drugs

First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

A Preliminary Study for INFORMED

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

STOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation

Catheter Ablation vs. Medical Therapy in Congested Hearts With AF

Comparison of QT Interval Readings Between Smartwatch Combined With Cardiologs Artificial Intelligence and 12-lead ECG

Determination of Rates and Reasons for Non-Adherence to Anti-Arrhythmic Therapy for Atrial Fibrillation

MANAGE-VT Registry - MANAGEment of Ventricular Tachycardia Outcomes Registry

Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence

Effects of Osteopathic Manipulative Therapy on Arrhythmias

High Intensity Focused Ultrasound (HIFU) Ablation System Study

Comparison of Recurrence of Atrial Fibrillation Post Cryoballon Ablation During the 90-day Blanking Period-with and Without Anti-arrhythmic Drug Therapy

Initial Management of Patients Receiving a Single Shock (IMPRESS)

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation

A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation

First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)